231 related articles for article (PubMed ID: 26335014)
41. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
[No Abstract] [Full Text] [Related]
42. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
43. Gemcitabine resistance in pancreatic cancer: picking the key players.
Kim MP; Gallick GE
Clin Cancer Res; 2008 Mar; 14(5):1284-5. PubMed ID: 18316544
[No Abstract] [Full Text] [Related]
44. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
Di Marco M; Di Cicilia R; Macchini M; Nobili E; Vecchiarelli S; Brandi G; Biasco G
Oncol Rep; 2010 May; 23(5):1183-92. PubMed ID: 20372829
[TBL] [Abstract][Full Text] [Related]
45. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
[TBL] [Abstract][Full Text] [Related]
46. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Maréchal R; Van Laethem JL
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
[TBL] [Abstract][Full Text] [Related]
48. Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer.
Hiraya D; Kagohashi K; Sakamoto N; Kondo T; Satoh H
JOP; 2010 Mar; 11(2):186-8. PubMed ID: 20208333
[No Abstract] [Full Text] [Related]
49. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma.
Mantoni TS; Schendel RR; Rödel F; Niedobitek G; Al-Assar O; Masamune A; Brunner TB
Cancer Biol Ther; 2008 Nov; 7(11):1806-15. PubMed ID: 18787407
[TBL] [Abstract][Full Text] [Related]
50. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
51. Transport properties of pancreatic cancer describe gemcitabine delivery and response.
Koay EJ; Truty MJ; Cristini V; Thomas RM; Chen R; Chatterjee D; Kang Y; Bhosale PR; Tamm EP; Crane CH; Javle M; Katz MH; Gottumukkala VN; Rozner MA; Shen H; Lee JE; Wang H; Chen Y; Plunkett W; Abbruzzese JL; Wolff RA; Varadhachary GR; Ferrari M; Fleming JB
J Clin Invest; 2014 Apr; 124(4):1525-36. PubMed ID: 24614108
[TBL] [Abstract][Full Text] [Related]
52. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Pham NA; Tsao MS; Cao P; Hedley DW
Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
[TBL] [Abstract][Full Text] [Related]
53. Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome.
Byrling J; Sasor A; Nilsson J; Said Hilmersson K; Andersson R; Andersson B
Scand J Gastroenterol; 2020 Jun; 55(6):725-731. PubMed ID: 32543919
[No Abstract] [Full Text] [Related]
54. Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.
Kreutzer JN; Ruzzene M; Guerra B
BMC Cancer; 2010 Aug; 10():440. PubMed ID: 20718998
[TBL] [Abstract][Full Text] [Related]
55. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
[TBL] [Abstract][Full Text] [Related]
56. p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.
Torres C; Mancinelli G; Cordoba-Chacon J; Viswakarma N; Castellanos K; Grimaldo S; Kumar S; Principe D; Dorman MJ; McKinney R; Hirsch E; Dawson D; Munshi HG; Rana A; Grippo PJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14724-14733. PubMed ID: 31266893
[TBL] [Abstract][Full Text] [Related]
57. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
58. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
59. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
[TBL] [Abstract][Full Text] [Related]
60. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.
Kim I; Choi YS; Song JH; Choi EA; Park S; Lee EJ; Rhee JK; Kim SC; Chang S
Mol Oncol; 2018 Sep; 12(9):1526-1539. PubMed ID: 30055072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
